Every Form 4 that Niagen Bioscience, Inc (NAGE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NAGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAGE filings page.
Niagen Bioscience SVP and General Counsel Carlos Luis Lopez acquired additional company stock through an employee plan. On this Form 4, he received 2,314 shares of common stock at a price of $2.71 per share under Niagen Bioscience’s Employee Stock Purchase Plan, in a transaction exempt under Rules 16b-3(c) and 16b-3(d). After this acquisition, his direct holdings increased to 4,565 common shares.
Niagen Bioscience Chief Financial Officer Pamir Ozan acquired additional company stock as part of compensation. Ozan received 4,255 shares of common stock at $2.71 per share through the Employee Stock Purchase Plan, increasing direct holdings to about 11,627 shares. The filing also shows indirect ownership of about 2,220 shares held by the CFO's spouse.
Niagen Bioscience, Inc. director and Chief Executive Officer Robert N. Fried acquired additional common shares through the company’s Employee Stock Purchase Plan. On June 30, 2026, he received 1,106 shares at $2.71 per share in a transaction classified as a grant or award acquisition exempt under Rule 16b-3(c) and 16b-3(d).
Following this acquisition, Fried directly holds 1,060,087 shares of Niagen Bioscience common stock. The filing also lists various indirect holdings held by trusts and family members, including shares held in irrevocable trusts for Benjamin and Jeremy Fried and in the Fried-Travis Revocable Trust, with the reporting person disclaiming beneficial ownership of these securities.
Niagen Bioscience director Yu Wing Tak Wendy received a grant of stock options covering 31,746 shares of Common Stock. The options have an exercise price of $3.45 per share, vest 100% on June 24, 2027, and expire on June 23, 2036. Following this compensation grant, she holds 31,746 stock options directly.
Niagen Bioscience, Inc. director Ng Wang Yu Gary reported a compensation-related stock option grant. He received an option to acquire 31,746 shares of common stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036. Following this grant, he holds options for 31,746 underlying shares directly.
Niagen Bioscience, Inc. director Ann Cohen received a grant of stock options covering 31,746 shares of common stock. The options have an exercise price of $3.45 per share and expire on June 23, 2036. They vest 100% on June 24, 2027, and following this award she holds 31,746 options directly.
Niagen Bioscience, Inc. director Patrick Kristin received a grant of stock options representing the right to buy 31,746 shares of common stock. The options have an exercise price of $3.4500 per share and vest 100% on June 24, 2027. After this grant, he holds 31,746 derivative securities linked to common stock, and the options expire on June 23, 2036.
Niagen Bioscience director Hamed Shahbazi received a new stock option grant. The award covers 31,746 shares of Common Stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036, with no shares sold in this filing.
Niagen Bioscience director Steven D. Rubin received a compensation-related grant of stock options. He was awarded 31,746 options to buy Common Stock at an exercise price of $3.45 per share. The options vest 100% on June 24, 2027 and expire on June 23, 2036. After this grant, he holds 31,746 derivative securities directly, with no open-market share purchases or sales reported in this filing.
Niagen Bioscience director Frank L. Jaksch Jr. received a compensation-related stock option grant. He was awarded options to acquire 31,746 shares of Common Stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036. Following this grant, he holds 31,746 derivative securities directly, with no open-market buying or selling reported in this filing.
Niagen Bioscience Chief Executive Officer Robert N. Fried exercised stock options to acquire 20,000 shares of Common Stock at an exercise price of $2.61 per share. He paid the exercise price in cash and, according to the footnotes, has not sold any of the shares received.
Following the exercise, Fried directly holds 1,058,981 shares of Common Stock. He also reports indirect holdings through family-related accounts and trusts, including 12,746 shares held by his sons and additional shares held in separate irrevocable and revocable trusts, while disclaiming beneficial ownership of those indirect securities.
Lopez Carlos Luis reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that its SVP and General Counsel, Carlos Luis Lopez, received a grant of employee stock options covering 41,420 shares on the reported grant date. The options were awarded at no purchase price on grant and will vest in four equal annual installments on each anniversary of the grant date.
Pamir Ozan reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that its Chief Financial Officer, Pamir Ozan, received a grant of employee stock options covering 62,131 shares of common stock. The options were awarded at no cost as part of his compensation.
According to the vesting terms, one-fourth of the options will vest on each anniversary of the grant date, spreading the potential ownership benefits over four years and tying them to continued service with the company.
Fried Robert N reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that Chief Executive Officer Robert N. Fried received a grant of employee stock options covering 503,937 shares on the reported date. The options were granted at no cash cost to him and are held directly. One-fourth of the options vest on each anniversary of the grant date, spreading vesting over four years.
Niagen Bioscience, Inc. (NAGE) reported insider share purchases by its Chief Financial Officer on a Form 4. On 11/14/2025, the CFO bought 4,464.962 shares of common stock in a direct transaction at a weighted average price of $6.81, with individual trade prices ranging from $6.7975 to $6.82. After this transaction, the CFO directly owned 7,372.159 shares of Niagen Bioscience common stock. On the same date, the CFO’s spouse acquired 2,220.443 shares at $6.85, which are reported as indirectly owned, bringing the indirect beneficial ownership to 2,220.443 shares.